The National Institutes of Health (NIH), the primary agency of the United States government responsible for biomedical and public health research, has long faced scrutiny regarding its allocation of taxpayer-funded grants to international research facilities. While the agency’s mission is to enhance health and reduce illness, a growing body of evidence suggests that hundreds of millions of dollars are directed annually toward foreign laboratories that engage in highly invasive animal experimentation. These projects, ranging from addiction studies to the induction of terminal diseases, have sparked a legislative movement in Washington D.C. aimed at halting the flow of federal funds to overseas animal testing sites.
The focal point of this legislative effort is the Cease Animal Research Grants Overseas (CARGO) Act, introduced as HR 1085 in the House and S 1802 in the Senate. If passed, the act would prohibit the NIH from awarding grants or contracts to foreign entities for any research involving the use of animals. Proponents of the bill argue that such a measure would not only save millions in taxpayer funds but also address a significant oversight gap, as foreign laboratories are not subject to the same rigorous on-site inspections as domestic facilities.
The Scope of International Funding and the CARGO Act
For decades, the NIH has utilized its multi-billion-dollar budget to support a global network of research. However, the lack of transparency regarding how these international sub-grantees treat animal subjects has become a point of contention. Unlike U.S.-based laboratories, which are subject to the Animal Welfare Act (AWA) and regular inspections by the U.S. Department of Agriculture (USDA), foreign institutions often operate under varying degrees of local regulation that may not align with American standards.
The CARGO Act seeks to close this loophole. By eliminating funding for overseas animal trials, the legislation aims to redirect resources toward domestic research or non-animal alternatives, such as organ-on-a-chip technology, computer modeling, and human-cell-based research. The bill comes at a time when the scientific community is increasingly debating the "translatability" of animal models to human health outcomes, with some data suggesting that over 90% of drugs that pass animal tests ultimately fail in human clinical trials.
Regional Case Studies: North America and Oceania
Canada: Invasive Procedures and High Financial Costs
Canada remains one of the largest recipients of NIH funding for animal-based research. At the University Health Network, experimenters have received over $3.7 million between 2014 and 2017 to induce strokes in rats and monkeys. Reports indicate that these procedures frequently resulted in brain hemorrhages and death within 24 hours. Furthermore, the same institution received $1.19 million for fiscal years 2024-2025 to perform lung transplants on pigs—a field known as xenotransplantation. These experiments involve "donor" pigs being euthanized for their organs, which are then placed into "recipient" pigs who are kept alive for imaging and tissue sampling before being bled to death.
At McGill University, research funded by the National Institute on Deafness and Other Communication Disorders (NIDCD) involved the intentional scarring of rabbit vocal cords. Between 2008 and 2025, approximately $6.5 million was allocated to studies where experimenters inserted spatulas into the throats of rabbits to ensure "adequate injury" for inflammation studies.
Australia: Infectious Disease and Addiction Studies
In Australia, the NIH has funded a variety of high-stakes biological experiments. The Walter and Eliza Hall Institute of Medical Research received $1.54 million (2023-2025) to infect animals with the parasite responsible for toxoplasmosis, a condition that causes seizures and diarrhea.
In the realm of substance abuse, Kinoxis Therapeutics was granted $5.95 million (2019-2024) by the National Institute on Drug Abuse (NIDA) to test molecules for opioid withdrawal. This research involved the forced addiction of nearly 1,500 mice, 314 rats, and 80 beagles. Critics point out that the physiological mechanisms of addiction in canines and rodents often fail to mirror the complex psychological and social drivers of human opioid dependency.
Oversight Failures in South America and the Caribbean
The risks associated with funding foreign laboratories are perhaps most evident in the case of the Caucaseco Scientific Research Center in Colombia. Funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung, and Blood Institute, the center received more than $17.6 million between 2003 and 2023.
Investigations into the facility revealed that owl monkeys and mice, infected with malaria for vaccine development, were kept in "filthy cages" and frequently abandoned to die without basic veterinary care. The scandal led to a rare move by the NIH to suspend funding, but only after two decades of operation. This case serves as a primary example for proponents of the CARGO Act, who argue that the NIH cannot effectively monitor animal welfare in distant jurisdictions.
In Chile, the Universidad de Concepción has received $2.38 million since the 1990s for alcohol-related research. These experiments involve injecting alcohol directly into the abdomens of mice or forcing them to consume high quantities of ethanol before subjecting them to behavioral stress tests, such as being suspended upside down by their tails.
European and Asian Research Initiatives
The United Kingdom: Stroke and Neurology
The UK has received significant NIH support for neurological research. At Newcastle University, $1.8 million was spent between 2021 and 2024 to surgically implant electrodes into the arms of monkeys before damaging their brains to simulate strokes. The goal was to monitor limb recovery, yet animal welfare advocates argue that the anatomical differences between primate and human brains often render these models inconclusive for human stroke rehabilitation.
Sweden and Finland: Invasive Brain Mapping
In Sweden, the Karolinska Institute has conducted several NIH-funded projects, including a $3.4 million study (2004-2024) where experimenters cut the spinal cords of rabbits and implanted electrodes in their legs to observe muscle responses. In Finland, the University of Helsinki received over $422,000 in 2021 to restrain fully awake rats while more than 500 electrodes were implanted into their brains, a state in which the animals were forced to live for months.
India and Germany: Genetic Modification and SIV
In India, the Indian Institute of Science used $241,992 (2023-2024) to genetically modify mice to suffer from chronic gut inflammation and diarrhea. Meanwhile, in Germany, the Universitätsklinikum Erlangen received $277,064 to infect monkeys with Simian Immunodeficiency Virus (SIV), a primate analog to HIV, despite the emergence of more sophisticated human-cell-based models for HIV research.
African and Middle Eastern Research Landscapes
NIH funding also extends into Africa, where research often focuses on parasitic diseases. In Kenya, Kenyatta University received $629,696 to infect hamsters with schistosomiasis, a disease that causes debilitating fever and muscle aches. In Nigeria, the Federal University of Technology was granted $393,634 to study the effects of high-fat and high-protein diets on rats, which were subsequently killed so their bladders could be removed for analysis.
In Tunisia, the Institut Pasteur de Tunis received nearly $250,000 for a project where rabbits were used as live bait for sandflies to study the transmission of leishmaniasis. These projects are often defended by the NIH as necessary for addressing "neglected tropical diseases," though the CARGO Act’s supporters argue that such research should be conducted using non-animal methodologies that are increasingly available.
Financial Data and Implications for Taxpayers
The financial implications of these grants are substantial. According to federal spending data, the NIH allocates a portion of its $45 billion annual budget to over 300 foreign institutions in more than 50 countries. Between 2011 and 2021, it is estimated that the NIH sent over $2.2 billion to foreign organizations.
The lack of a centralized, real-time tracking system for animal welfare violations in these foreign labs makes it difficult for the American public to assess the "return on investment" for these funds. Economists and policy analysts have noted that the indirect costs—including the administrative burden of managing international grants and the potential for scientific fraud in less-regulated environments—further complicate the value proposition of these expenditures.
Scientific and Ethical Debates
The ethical debate surrounding animal testing is often framed as a conflict between "medical progress" and "animal cruelty." However, a third dimension—"scientific validity"—is becoming the dominant argument for legislative change.
- Translatability: Critics of animal research, such as the Physicians Committee for Responsible Medicine (PCRM), argue that the biological differences between species are too significant to overcome. They point to the high failure rate of Alzheimer’s and cancer drugs that showed promise in mice but were ineffective or toxic in humans.
- Technological Advancement: The rise of New Approach Methodologies (NAMs) offers a potential path forward. Technologies like 3D bioprinting of human tissues and high-speed computer simulations can often provide more accurate data on human drug metabolism than animal subjects.
- Ethical Standards: The "exportation" of animal testing is seen by some as an ethical bypass. If a procedure is deemed too cruel or ethically questionable to be performed easily in the United States, performing it in a foreign laboratory with less oversight is viewed by advocates as a moral inconsistency.
Official Responses and the Path Forward
The NIH has historically defended its international grants, stating that global collaboration is essential for tackling pandemics and rare diseases. In public statements, the agency has emphasized that all grantees are expected to follow the "International Guiding Principles for Biomedical Research Involving Animals." However, the agency has admitted that it does not conduct its own on-site inspections of foreign labs, instead relying on "self-reporting" and documentation from the host country’s regulatory bodies.
The introduction of the CARGO Act has prompted mixed reactions on Capitol Hill. While some lawmakers are concerned about potentially slowing down medical research, a bipartisan coalition of fiscal conservatives and animal welfare advocates has rallied behind the bill. They argue that if the research is vital, it should be conducted in the U.S. where it can be properly overseen, or it should transition to modern, non-animal methods.
As the CARGO Act moves through congressional committees, it serves as a catalyst for a broader discussion on the transparency of federal spending. Whether the act passes or not, the spotlight on foreign laboratory practices has already led to increased demands for accountability. For the American taxpayer, the question remains: is the current model of international animal experimentation a necessary component of modern medicine, or is it an outdated practice that persists only because it remains out of sight and out of mind?
